Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Human bladder carcinoma line LB831-BLC expresses several distinct Ags that are recognized by different autologous CTL. Here, we show that one of these Ags is presented by HLA-Cw7 and encoded by gene MAGE-A12. This is the first time that CTL directed against a MAGE-encoded Ag have been derived from the lymphocytes of a patient with cancer other than melanoma. This new Ag was found to be nonapeptide VRIGHLYIL, corresponding to position 170-178 of the MAGE-A12 protein. Gene MAGE-A12 is silent in normal tissues except in male germline cells, which do not express HLA molecules. It is expressed in 26-62% of melanomas, infiltrating bladder carcinomas, lung carcinomas, esophageal carcinomas, and head and neck carcinomas. Because HLA-Cw7 is present in 43% of Caucasians, this new Ag is shared by many tumors and should be a useful target for cancer immunotherapy.

Type

Journal article

Journal

J Immunol

Publication Date

01/06/2000

Volume

164

Pages

6041 - 6045

Keywords

Aged, Antigen Presentation, Antigens, Neoplasm, Clone Cells, Esophageal Neoplasms, Genes, Neoplasm, Head and Neck Neoplasms, Humans, Lung Neoplasms, Male, Melanoma, Neoplasm Proteins, Peptide Fragments, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Urinary Bladder Neoplasms